Method for preparing amino acid with improved filtration flux

MYPI2025000214A0Undetermined Publication Date: 2024-09-14CJ CHEILJEDANG CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025000214
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-14
Filing Date
2024-03-14
Publication Date
2024-09-14

AI Technical Summary

Technical Problem

The production of branched-chain amino acids using microorganisms faces challenges in mass production due to issues with membrane filtration, where impurities deposit on the membrane surface, reducing permeation flux and increasing maintenance and production costs.

Method used

Adding an organic coagulant and/or cationic polymer flocculant to the culture medium to precipitate impurities, followed by membrane filtration, which improves membrane permeation flux and reduces membrane contamination.

Benefits of technology

This method enhances membrane permeation flux, extends membrane life, and increases productivity by reducing impurity deposition, thereby improving economic efficiency and product quality.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure relates to a method for preparing an amino acid, comprising adding a coagulant and / or a flocculant to a culture broth comprising the amino acid.
Need to check novelty before this filing date? Find Prior Art

Description

Method for producing amino acids with improved filtration rate

[0001] The present application relates to a method for producing an amino acid having improved filtration flux, comprising the step of adding a coagulant and / or a flocculant to a culture solution containing the amino acid.

[0002]

[0003] Amino acids are the basic building blocks of proteins and are used as key ingredients in pharmaceutical raw materials, food additives, animal feed, nutritional supplements, pesticides, and disinfectants. Branched-chain amino acids (BCAAs) are a general term for the essential amino acids valine, leucine, and isoleucine. These BCAAs are known to have antioxidant properties and directly promote protein synthesis in muscle cells.

[0004] Meanwhile, the production of branched-chain amino acids using microorganisms is primarily accomplished through microorganisms of the genus Escherichia or the genus Corynebacterium, and is known to biosynthesize 2-ketoisocaproic acid as a precursor from pyruvate through several steps. However, the production of branched-chain amino acids using these microorganisms presents the problem of difficulty in mass production industrially.

[0005] Meanwhile, a typical amino acid manufacturing process is performed by including a series of steps such as i) microbial culture, ii) filtration of the culture solution containing amino acids, iii) decolorization, iv) filtration, v) concentration, and vi) crystallization, and here, unit processes may be added or subtracted depending on the product characteristics. Among the above processes, the 'filter process' is a process that removes the cells, proteins, colloidal substances, natural organic matter (NOM), and low-molecular substances contained in the culture solution using a filter membrane. In the above filtration process, when the culture solution is filtered through a membrane, impurities are deposited on the membrane over time, and a gel-like cake layer is formed on the membrane surface. This membrane fouling reduces the membrane flux. If the membrane flux decreases, the daily product production decreases, the filtration membrane cleaning cycle becomes longer, and the membrane replacement cycle becomes shorter, which induces an increase in maintenance costs and an increase in production unit price, resulting in a loss of price competitiveness. Therefore, in order to suppress the formation of a cake layer by impurities on the membrane surface, which causes a decrease in membrane permeation flux, a method is required that can remove impurities in a culture medium or reduce membrane contamination by impurities during a filtration process.

[0006]

[0007] One object of the present application is to provide a method for producing an amino acid from a culture solution containing an amino acid, comprising the steps of: (a) adding an organic coagulant, a cationic polymer flocculant, or both to a culture solution containing an amino acid to precipitate impurities; and (b) membrane-filtering the culture solution in which the impurities have been precipitated.

[0008] Another object of the present application is to provide a feed composition comprising an amino acid produced by the method of the present application.

[0009]

[0010] This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in this application can also be applied to each other description and embodiment. In other words, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the scope of this application is not limited by the specific descriptions described below.

[0011] Additionally, numerous papers and patents are referenced and cited throughout this specification. The disclosures of these cited papers and patents are incorporated herein by reference in their entirety, thereby providing a clearer understanding of the technical field to which this application pertains and the content of this application.

[0012]

[0013] In order to achieve the above object, one aspect of the present application provides a method for producing an amino acid from a culture solution containing an amino acid, comprising the steps of: (a) adding an organic coagulant, a cationic polymer flocculant, or both to a culture solution containing an amino acid to precipitate impurities; and (b) membrane-filtering the culture solution in which the impurities have been precipitated.

[0014]

[0015] The term "coagulant" as used herein may refer to a substance that causes particles in a liquid to coagulate (curdle) or clot (clot) together, thereby allowing them to separate from the liquid. Specifically, it refers to a substance that promotes the aggregation of fine particles in a liquid into larger clumps. For example, particles in a liquid carry surface charges that repel each other, so they remain suspended in water without settling. A coagulant imparts an opposite charge to these particles, destabilizing the charge and resulting in the particles sticking together (clinging). The coagulant is applied across a wide range of industries, from food, beverages, chemicals, and pharmaceuticals to drinking water, municipal wastewater treatment, and oil and gas drilling. It can be used to precipitate relatively small particles, primarily those several μm in size, for example, around 2 μm.

[0016] The term "flocculant" (also known as a "flocculating agent" or "flocking agent") used in this application refers to a substance used to remove suspended solids from a liquid by inducing coagulation, such as when solids aggregate and begin to form flakes that settle to the bottom. The larger and / or heavier particles formed in this process are also called flocs. Unlike coagulants, which induce chemical coagulation by destabilizing electrical charges, coagulants promote physical coagulation by agglomerating colloids and other suspended particles in a liquid to form flocs. Such coagulants are also used in filtration processes such as water treatment processes to settle small particles and improve filterability. They can be mainly used to settle relatively large particles of 10 μm or more.

[0017] For example, the coagulant or flocculant used in the manufacturing method of the present application may be an organic coagulant, a cationic polymer coagulant, or a combination thereof.

[0018] Specifically, the organic coagulant may include a component such as poly(dimethylamine-co-epichlorohydrin; EPI-AMINE) or poly(diallyldimethylammonium chloride; polyDADMAC); and the cationic polymer coagulant may include a long chain polymer component such as polyacrylamide (PAM), polyethylenimine (PEI), or polyvinylamine (PVAM), but is not limited thereto.

[0019]

[0020] For example, the manufacturing method of the present application may additionally include a step of adjusting the culture medium containing the amino acid to an acidic pH of 3 to 5. For example, the culture medium containing the amino acid may be adjusted to a pH of 3.0 to 4.5, a pH of 3.5 to 4.0, a pH of 3.7 to 4.3, or a pH of 3.8 to 4.2, but is not limited thereto. In a specific example of the present application, it was confirmed that the coagulation efficiency by the coagulant or coagulant was affected by the pH condition of the solution, and in particular, it was confirmed that the coagulation efficiency was improved under acidic conditions compared to neutral conditions. However, the coagulation efficiency by the coagulant or coagulant is affected by the concentration of the coagulant or coagulant, the type of amino acid to be produced, the type, size, and / or amount of impurities in the culture medium, in addition to the pH condition, and therefore the scope of the present application is not limited to the pH condition.

[0021]

[0022] The amino acid production method of the present application is characterized by an improved filtration flux of membrane filtration compared to when not treated with a coagulant and / or flocculant.

[0023] Furthermore, the amino acid production method of the present application can have the effect of improving the color of the membrane-filtrated filtrate and reducing the content of impurities.

[0024]

[0025] For example, a culture medium containing amino acids may contain as impurities one or more selected from the group consisting of bacterial cells, proteins, colloidal substances, natural organic matter (NOM), and low-molecular-weight substances. For example, a culture medium for producing amino acids may contain various impurities, including not only suspension materials such as bacterial cells, but also colloidal substances derived from fermentation by-products such as fermentation medium and cell lysate, and these particles may adhere to the membrane to form a cake during the filtration process applied to the subsequent amino acid production process, thereby lowering filtration efficiency and contaminating the membrane and shortening the membrane replacement cycle, thereby adversely affecting productivity. Meanwhile, the use of a coagulant and / or a flocculant in the manufacturing method of the present application can significantly reduce contamination such as forming a cake on the membrane by coagulating / condensing and precipitating these impurities, thereby improving membrane permeation flux and extending the life of the membrane, thereby improving productivity as well as the economic feasibility of production.

[0026]

[0027] In the present application, the culture medium containing the amino acid may be obtained through fermentation by microorganisms, but is not limited thereto. In this case, the fermentation by microorganisms may be performed using any method known in the art without limitation.

[0028]

[0029] For example, the manufacturing method of the present application may additionally include a pretreatment step of separating the cells from the culture medium containing amino acids. For example, the cell separation may be performed using a mechanical separator (MS) or a membrane filter (MF), but is not limited thereto. In this case, the cell separation using a mechanical separator mainly uses centrifugation, but in such cases, colloidal substances may not be separated and may be transferred to the filtrate. Therefore, when combined with the manufacturing method of the present application, a particularly remarkable improvement effect can be achieved.

[0030]

[0031] The term "culture solution" in this application refers to a culture obtained by culturing microorganisms. The culture solution may contain the cultured microorganisms. Furthermore, the culture solution may be used interchangeably with "fermentation solution."

[0032] The term “culture solution containing amino acids” in the present application may be used interchangeably with “culture solution containing amino acids” or “amino acid culture solution.”

[0033] In the present application, the culture solution containing the amino acid may be, but is not limited to, a fermented product containing cells obtained according to a known microbial fermentation method (US 8465962 B2, US 9885093 B2, US 10351859 B2, US 7863435 B2, US 10787692 B2, US 9029105 B2, US 2021-0094903 A1), a liquid itself from which cells are removed from the fermented product, or a concentrate obtained by concentrating the same.

[0034] Specifically, the culture solution containing the amino acid of the present application can be obtained by culturing or fermenting a microorganism that produces the amino acid, and the microorganism and the culture or fermentation method thereof can be selected and used by a person skilled in the art from known types and methods. For example, the microorganism includes both a wild-type microorganism and a microorganism that has undergone genetic modification naturally or artificially, and may be a microorganism in which a specific mechanism has been weakened or strengthened due to causes such as the insertion of an external gene or the enhancement or inactivation of the activity of an endogenous gene, and may be a microorganism in which a genetic mutation has occurred or the activity has been enhanced for the production of the desired L-amino acid (US 9587261 B2, US 7863435 B2, etc.). Specifically, the above microorganism is not particularly limited in type as long as it can produce the desired amino acid, but may be a microorganism belonging to the genus Enterbacter, Escherichia, Erwinia, Serratia, Providencia, Corynebacterium, and Brevibacterium. More specifically, it may be a microorganism belonging to the genus Corynebacterium or Escherichia.The above Corynebacterium genus microorganisms include Corynebacterium glutamicum, Corynebacterium ammoniagenes, Corynebacterium thermoaminogenes, Corynebacterium efficiens, Corynebacterium stationis, Corynebacterium phocae, Corynebacterium flavescens, Corynebacterium humireducens, Corynebacterium halotolerans, Corynebacterium pollutisoli, The microorganism of the genus Escherichia may be, but is not limited to, Escherichia coli, but is not limited to, Corynebacterium marinum, Corynebacterium freiburgense, Corynebacterium cystitidis, Corynebacterium durum, Corynebacterium pilosum, or Corynebacterium testudinoris.

[0035]

[0036] In addition, the manufacturing method of the present application may optionally further include, after the membrane filtration step, one or more steps selected from the group consisting of a decolorization step; a filtrate concentration step; a crystallization step; a crystal separation step; a drying step; a sieving step; and a product manufacturing step. Each of the above steps may be performed without limitation using methods known in the art (e.g., US 2021-0094903 A1). Furthermore, specific conditions may be appropriately modified to optimize the process, but are not limited thereto.

[0037]

[0038] For example, the amino acid that can be produced using the manufacturing method of the present application may be isoleucine, valine, or leucine, but is not limited thereto. Depending on the type of amino acid to be produced, the type and / or size of impurities contained in the culture medium may vary. Therefore, for the amino acid to be produced, a coagulant or flocculant suitable for improving membrane permeation flux may be selected and used, or a combination of both may be used, taking into account the above factors.

[0039]

[0040] Another aspect of the present application provides a feed composition comprising an amino acid prepared by the method of the present application.

[0041] The amino acids of the present invention may be suitable for use as feed additives in the manufacture of animal feed. For example, the amino acids as feed additives may be mixed with feed materials themselves, as part of an animal feed premix or as precursors to animal feed. A feed composition comprising the amino acids may be administered to animals alone or in combination with other feed additives in an edible carrier. Furthermore, the feed compositions may be readily administered to animals as top dressings, by mixing them directly into animal feed, or in an oral formulation separate from the feed.

[0042]

[0043] The manufacturing method of the present application improves productivity by adding a coagulant and / or a flocculant to the culture solution to precipitate impurities contained in the culture solution, thereby reducing membrane contamination in the subsequent filtration process and improving membrane permeation flux, and also improves the quality of the product produced by reducing the content of proteins and color substances in the filtrate.

[0044]

[0045] Hereinafter, the present application will be described in more detail with reference to the following examples. However, the following examples are intended only to illustrate the present application and are not intended to limit the scope of the present application.

[0046]

[0047] Example 1: Effect of adding coagulants / flocculants in coagulation experiments

[0048]

[0049] Amino acid culture solutions produced using microorganisms were used as process solutions. The amino acid culture solutions supplied included isoleucine culture solutions, valine culture solutions, and leucine culture solutions. To test membrane filtration efficiency, a large number of bacterial cells with large particle sizes were removed by centrifugation using a mechanical separator (Alfa Laval Seperator), and the supernatant was used as feed for membrane filtration tests. The pH of the feed solution was 6, and the pH was adjusted using 98% H2SO4 and 50% NaOH.

[0050] Specifically, for the membrane filtration experiment, 200 mL of the separated solution of the amino acid culture solution from which the fungi had been primarily removed was prepared, and the pH was adjusted with 98% H2SO4 and 50% NaOH. 200 ppm of each of the seven coagulants / flocculants listed in Table 1 was added to each pH-adjusted solution, and the solution was allowed to settle for 30 minutes after rapid stirring for 10 seconds and slow stirring for 30 seconds, and then filtered through a Nutsche filter with a diameter of 3.6 cm and a membrane area of ​​0.001 m.2 The filter cloth was fixed and filtered under reduced pressure. The process solution was separated into solid (cake), which is the precipitated aggregate, and liquid filtrate (filtrate). The average membrane flux was measured based on the time it took for 200 mL of filtrate to be discharged, and the unit membrane area (m) per unit time (hr) was 2 ) was calculated as the flow rate (L) passing through:

[0051] .

[0052]

[0053] Product name Ingredient Chemical name CAS No. Active ingredient content (%) Average molecular weight (Mw) BASF Magnafloc LT-7991 EPI-AMINE poly(dimethylamine-co-epichlorohydrin) 42751-79-150 (remaining water) 150,000-300,000 BASF Magnafloc LT-7994 polyDADMAC poly(diallyldimethylammonium chloride) 26062-79-340 (remaining water) 200,000-350,000 BASF Zetag 8185 PAM polyacrylamide 9003-05-08 8.75 ↑ 10,000,000 BASF Zetag ® IP 2MPEIpolyethylenimine 114133-44-724 (remaining water) 2,000,000BASFHercobond™ 6960PVAMpolyvinylamine (formamide, ethenyl-, homopolymer, dimapa-quat conjugate, hydrochloride) 1353435-58-110 (remaining water) 34,000-1,500,000BIOSYNTHFP31706PACpolyaluminum chloride 1327-41-9min 99100-1000Sigma-Aldrich434957APAMpoly(acrylamide-co-acrylic acid) 9003-06-98715,000,000

[0054] Example 2: Effect of pH in coagulation experiments

[0055]

[0056] In the above coagulation experiment, in order to confirm the effect according to pH, the experiment was performed as in Example 1, but the pH was adjusted to 4, which is an acidic range, 6, which is a neutral range, and 8, which is a basic range, and coagulation was confirmed in each. The results are shown in Tables 2 to 7 below, and briefly, regardless of the type of coagulant / coagulant, no precipitation was observed at pH 6 and 8, and at acidic pH 4, it was shown that precipitation was formed or not formed depending on the presence / absence and / or type of the coagulant / coagulant. This indicates that the combination of an appropriate coagulant / coagulant addition and an acidic pH can promote precipitation, further improve the filtration flux, and improve the quality of the filtrate.

[0057]

[0058] Example 3: Effect of coagulant / flocculant addition and pH on the production of isoleucine.

[0059]

[0060] As in Example 1, a membrane filtration experiment was performed using the separated solution of the amino acid culture solution from which the primary cells were removed as a feed solution, but the amino acid culture solution was a culture solution containing isoleucine, the pH was adjusted to 4, 6, or 8, and the experiment was conducted with or without the coagulant / flocculant of Table 1. As in Example 1, the formation of sediment in each sample was observed, and the permeation flux was calculated, and the results are shown in Tables 2 and 3. In addition, the absorbance at 280 nm and 420 nm, which are used as protein content indicators and color indicators, respectively, for the filtrates obtained in each case were measured, and the results are shown together in Tables 2 and 3.

[0061]

[0062]

[0063]

[0064] As shown in Tables 2 and 3 above, in the tested isoleucine production process, no precipitation was observed from the samples without coagulant / flocculant addition regardless of the pH, and the permeate flux also showed a low value. In the coagulant / flocculant addition groups, when APAM was added, no precipitation was formed regardless of the pH, just like the non-added control group, and no improvement in permeate flux was observed compared to the non-added control group. On the other hand, in the case of the group adding inorganic coagulant PAC, precipitation was formed at pH 4, but the improvement in permeate flux was minimal, and no precipitation was formed in other pH ranges. On the other hand, in the groups adding EPI-AMINE, polyDADMAC, PAM, PEI, or PVAM, no precipitation was formed in the experimental groups adjusted to pH 6 and 8, and no improvement in permeate flux was observed, but in the experimental group adjusted to pH 4, precipitation was observed and a significant increase in permeate flux was observed. In particular, PAM demonstrated a 5.7-fold improvement in filtration flux. Furthermore, these experimental groups exhibited a significant reduction in absorbance at 420 nm, a colorimetric indicator. This demonstrates that the process can improve filtrate quality.

[0065]

[0066] Example 4: Effect of coagulant / flocculant addition and pH in the production of valine.

[0067]

[0068] As in Example 1, a membrane filtration experiment was performed using the separated solution of the amino acid culture solution from which the primary cells were removed as a feed solution, but the amino acid culture solution was a culture solution containing valine, the pH was adjusted to 4 or 6, and the experiment was conducted with or without the coagulant / flocculant of Table 1. As in Example 1, the formation of sediment in each sample was observed, and the permeation flux was calculated, and the results are shown in Tables 4 and 5. In addition, the absorbance at 280 nm and 420 nm, which are used as protein content indicators and color indicators, respectively, for the filtrates obtained in each case were measured, and the results are shown together in Tables 4 and 5.

[0069]

[0070]

[0071]

[0072]

[0073] As shown in Tables 4 and 5 above, in the tested valine production process, no precipitation was observed from the samples without coagulant / flocculant added, regardless of the pH, and the permeate flux also showed a low value. In the groups with coagulant / flocculant added, when APAM was added, no precipitation was formed regardless of the pH, just like the control group without added, and no improvement in permeate flux was observed compared to the control group without added. On the other hand, in the group with inorganic coagulant PAC added, precipitation was formed at pH 4, but the improvement in permeate flux was minimal, and no precipitation was formed in other pH ranges. On the other hand, in the groups with EPI-AMINE, polyDADMAC, PAM, PEI, or PVAM added, no precipitation was formed in the experimental group adjusted to pH 6, and no improvement in permeate flux was observed, but in the experimental group adjusted to pH 4, precipitation was observed and a significant increase in permeate flux was observed. In particular, polyDADMAC demonstrated a 4.0-fold improvement in filtration flux. Furthermore, these experimental groups exhibited a significant reduction in absorbance at 420 nm, a colorimetric indicator. This demonstrates that the process can improve filtrate quality.

[0074]

[0075] Example 5: Effect of coagulant / flocculant addition and pH on the production of leucine.

[0076]

[0077] As in Example 1, a membrane filtration experiment was performed using the separated solution of the amino acid culture solution from which the primary cells were removed as a feed solution, but the amino acid culture solution was a culture solution containing leucine, the pH was adjusted to 4 or 6, and the experiment was conducted with or without the coagulant / flocculant of Table 1. As in Example 1, the formation of sediment in each sample was observed, and the permeation flux was calculated, and the results are shown in Tables 6 and 7. In addition, the absorbance at 280 nm and 420 nm, which are used as protein content indicators and color indicators, respectively, for the filtrates obtained in each case, were measured, and the results are shown together in Tables 6 and 7.

[0078]

[0079]

[0080]

[0081]

[0082] As shown in Tables 2 to 7 above, in the tested leucine production process, no precipitation was observed from the samples without coagulant / flocculant addition regardless of the pH, and the permeate flux also showed a low value. In the groups with coagulant / flocculant addition, when APAM was added, no precipitation was formed regardless of the pH, just like the control group without addition, and no improvement in permeate flux was observed compared to the control group without addition. On the other hand, in the group with inorganic coagulant PAC addition, precipitation was formed at pH 4, but the improvement in permeate flux was minimal, and no precipitation was formed in other pH ranges. On the other hand, in the groups with EPI-AMINE, polyDADMAC, PAM, PEI, or PVAM addition, no precipitation was formed in the experimental group adjusted to pH 6, and no improvement in permeate flux was observed, but in the experimental group adjusted to pH 4, precipitation was observed and a significant increase in permeate flux was observed. In particular, PAM demonstrated a 4.0-fold improvement in filtration flux. Furthermore, these experimental groups exhibited a significant reduction in absorbance at 420 nm, a colorimetric indicator. This demonstrates that the process can improve filtrate quality.

[0083]

[0084] In summary, the manufacturing method of the present application, which additionally includes a step of adding a coagulant / flocculant prior to membrane filtration, can significantly improve the average membrane permeation flux while maintaining the concentration rate at the same level as when the coagulant / flocculant is not added, and thus can significantly increase the daily production of amino acids, suggesting that it can provide an improved method with an advantage in price competitiveness. Furthermore, the manufacturing method of the present application has been confirmed to significantly reduce the absorbance at 420 nm, which is a product condition specification requirement in the food amino acid industry, by efficiently removing impurities including color substances as well as proteins, and thus can be usefully utilized for improving the quality of amino acid products.

[0085]

[0086] From the above description, those skilled in the art will understand that the present application can be implemented in other specific forms without altering its technical concept or essential characteristics. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of this application should be interpreted as encompassing all changes or modifications derived from the meaning and scope of the following claims and their equivalents, rather than the detailed description above.

Claims

1. A method for producing amino acids from a culture solution containing amino acids, (a) a step of precipitating impurities by adding an organic coagulant, a cationic polymer flocculant, or both to a culture solution containing amino acids; and (b) a step of filtering the culture solution in which the impurities have been precipitated; Method for producing amino acids.

2. In paragraph 1, A method for producing an amino acid, wherein the organic coagulant is poly(dimethylamine-co-epichlorohydrin; EPI-AMINE) or poly(diallyldimethylammonium chloride; polyDADMAC), and the cationic polymer coagulant is polyacrylamide (PAM), polyethylenimine (PEI), or polyvinylamine (PVAM).

3. In paragraph 1, A method for producing an amino acid, further comprising a step of adjusting the acidity of a culture solution containing the amino acid to a pH of 3 to 5.

4. In paragraph 1, A method for producing an amino acid, wherein the filtration flux of the above membrane filtration is improved.

5. In paragraph 1, A method for producing an amino acid, wherein the color of the filtered liquid is improved and the content of impurities is reduced.

6. In paragraph 1, A method for producing an amino acid, wherein the impurity is at least one selected from the group consisting of fungi, proteins, colloidal substances, natural organic matter (NOM), and low molecular substances.

7. In paragraph 1, A method for producing an amino acid, wherein the culture medium containing the above amino acid is obtained through fermentation by a microorganism.

8. In paragraph 1, A method for producing an amino acid, further comprising a pretreatment step of separating a fungus from a culture medium containing the amino acid.

9. In paragraph 1, A method for producing an amino acid, which further comprises, after the above-mentioned membrane filtration step, optionally, at least one step selected from the group consisting of a decolorization step; a filtrate concentration step; a crystallization step; a crystal separation step; a drying step; a sieving step; and a product manufacturing step.